

## MEDIA STATEMENT

PHILOGEN SPA ANNOUNCES PARTECIPATION IN "XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY", 28 AUGUST – 1 SEPTEMBER 2016, MANCHESTER, UK

<u>Philogen S.p.A.</u> and its fully owned subsidiary <u>Philochem AG</u>, announce their participation to the "XXIV EFMC International Symposium on Medicinal Chemistry" that will take place at the Manchester Central Convention Complex from August 28 to September 1, 2016.

The five-day symposium will gather nearly 25 member societies and about 7.500 members. In this symposium edition, particular emphasis will be put on the recent progress in medicinal chemistry and the impact of novel organic synthesis in drug discovery.

**Dario Neri**, the co-founder and chairman of the scientific advisory board of Philogen, will deliver a plenary lecture with the title "'DNA-Encoded Chemical Libraries". The presentation is scheduled to take place on Wednesday, August 31<sup>st</sup>.

**Philochem AG** will participate as an exhibitor with a booth to present its patent-protected DNA-Encoded Chemical Libraries (DECL) technology and also provide demonstrations of its proprietary software for efficient data processing, statistical analysis and result visualization.

For additional news and press release topics, visit: http://www.philogen.com/en/news/

## **About the Philogen group**

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com